Lif welcomes Denmark’s proposal for Cancer Plan V

20 January 2025

There are good points in the Danish National Board of Health's professional presentation for Cancer Plan V, which was presented last week, according to the local pharma trade group, Lif.

The presentation contains 11 specific recommendations, divided into three general topics: Individualization, Interventions after a cancer illness, and quality of interventions.

"With a focus on early detection and diagnostics as well as life after cancer and palliation, there is reason to be pleased that cancer treatment has been considered in all phases of the process," says Ida Sofie Jensen, chief executive of the Lif.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK